Corbus Pharmaceuticals Holdings, Inc. (CRBP): Price and Financial Metrics

Corbus Pharmaceuticals Holdings, Inc. (CRBP): $0.30

-0.01 (-2.45%)

POWR Rating

Component Grades













Add CRBP to Watchlist
Sign Up

Industry: Biotech



in industry


  • CRBP scores best on the Sentiment dimension, with a Sentiment rank ahead of 92.46% of US stocks.
  • CRBP's strongest trending metric is Growth; it's been moving down over the last 179 days.
  • CRBP's current lowest rank is in the Momentum metric (where it is better than 4.64% of US stocks).

CRBP Stock Summary

  • With a price/sales ratio of 76.71, Corbus Pharmaceuticals Holdings Inc has a higher such ratio than 97.09% of stocks in our set.
  • As for revenue growth, note that CRBP's revenue has grown -77.61% over the past 12 months; that beats the revenue growth of only 1.51% of US companies in our set.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for CRBP comes in at -92.62% -- higher than that of only 4.35% of stocks in our set.
  • Stocks that are quantitatively similar to CRBP, based on their financial statements, market capitalization, and price volatility, are CYCN, ONCT, SLDB, ACET, and STRO.
  • Visit CRBP's SEC page to see the company's official filings. To visit the company's web site, go to

CRBP Valuation Summary

  • In comparison to the median Healthcare stock, CRBP's price/sales ratio is 432.16% higher, now standing at 60.4.
  • CRBP's price/sales ratio has moved NA NA over the prior 83 months.
  • CRBP's price/earnings ratio has moved up 46.2 over the prior 83 months.

Below are key valuation metrics over time for CRBP.

Stock Date P/S P/B P/E EV/EBIT
CRBP 2021-08-31 60.4 2.1 -2.1 -2.0
CRBP 2021-08-30 55.7 1.9 -1.9 -1.9
CRBP 2021-08-27 58.1 2.0 -2.0 -1.9
CRBP 2021-08-26 56.7 2.0 -2.0 -1.9
CRBP 2021-08-25 58.5 2.0 -2.0 -2.0
CRBP 2021-08-24 60.0 2.1 -2.1 -2.0

CRBP Growth Metrics

    Its 3 year net income to common stockholders growth rate is now at -587.86%.
  • The 2 year net income to common stockholders growth rate now stands at -104.29%.
  • Its 5 year revenue growth rate is now at 3346.95%.
CRBP's revenue has moved down $1,934,160 over the prior 52 months.

The table below shows CRBP's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 0.881705 -48.1837 -45.64043
2021-09-30 1.539909 -56.70543 -43.9916
2021-06-30 2.673207 -84.8155 -76.7108
2021-03-31 2.822995 -93.89405 -97.67775
2020-12-31 3.93723 -99.6857 -111.2694
2020-09-30 5.852546 -104.0233 -129.2382

CRBP's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CRBP has a Quality Grade of C, ranking ahead of 45.96% of graded US stocks.
  • CRBP's asset turnover comes in at 0.023 -- ranking 364th of 681 Pharmaceutical Products stocks.
  • ARNA, ARWR, and MRSN are the stocks whose asset turnover ratios are most correlated with CRBP.

The table below shows CRBP's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.023 1 -1.703
2021-03-31 0.026 1 -4.511
2020-12-31 0.044 1 -168.104
2020-09-30 0.076 1 31.788
2020-06-30 0.103 1 20.133
2020-06-30 0.103 1 20.133

CRBP Price Target

For more insight on analysts targets of CRBP, see our CRBP price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $1.88 Average Broker Recommendation 1.9 (Hold)

CRBP Stock Price Chart Interactive Chart >

Price chart for CRBP

CRBP Price/Volume Stats

Current price $0.30 52-week high $2.29
Prev. close $0.30 52-week low $0.21
Day low $0.29 Volume 459,992
Day high $0.31 Avg. volume 1,446,816
50-day MA $0.38 Dividend yield N/A
200-day MA $0.70 Market Cap 36.95M

Corbus Pharmaceuticals Holdings, Inc. (CRBP) Company Bio

Corbus Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, focuses on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases. The company is based in Norwood, Massachusetts.

CRBP Latest News Stream

Event/Time News Detail
Loading, please wait...

CRBP Latest Social Stream

Loading social stream, please wait...

View Full CRBP Social Stream

Latest CRBP News From Around the Web

Below are the latest news stories about Corbus Pharmaceuticals Holdings Inc that investors may wish to consider to help them evaluate CRBP as an investment opportunity.

Investors Financial Group, LLC Buys USHG Acquisition Corp, Daktronics Inc, Weber Inc, Sells MP ...

Investment company Investors Financial Group, LLC (Current Portfolio) buys USHG Acquisition Corp, Daktronics Inc, Weber Inc, Verizon Communications Inc, Boeing Co, sells MP Materials Corp, Hyzon Motors Inc, JPMorgan Chase.

Yahoo | January 14, 2022

JTC Team to Host Virtual Investor 2022 Top Picks Conference on January 25th, 26th, and 27th

\- Access the event and schedule of presenting companies at -\- Live video webcast presentations of participating companies followed by interactive Q&A session -PITTSTOWN, NJ / ACCESSWIRE / January 12, 2022 /JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced it will host the Virtual Investor 2022 Top Picks Conference January 25-27, 2022.

Yahoo | January 12, 2022

Here's Why You Should Hold Onto Acadia Healthcare (ACHC) Now

Acadia Healthcare (ACHC) is poised for growth due to higher revenues driven by solid demand for behavioral health services, multiple JVs with established healthcare systems and debt repayment efforts.

Yahoo | December 31, 2021

After Plunging 29.4% in 4 Weeks, Here's Why the Trend Might Reverse for Corbus Pharmaceuticals (CRBP)

The heavy selling pressure might have exhausted for Corbus Pharmaceuticals (CRBP) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Yahoo | December 29, 2021

Corbus Pharmaceuticals Holdings Inc. (CRBP) Shares Are Down -47.68% YTD

Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) has a beta value of 1.79 and has seen 1.45 million shares traded in the recent trading session. The company, currently valued at $81.66M, closed the recent trade at $0.64 per share which meant it lost -$0.01 on the day or -2.37% during that session. The CRBP stock price is … Corbus Pharmaceuticals Holdings Inc. (CRBP) Shares Are Down -47.68% YTD Read More »

Marketing Sentinel | December 21, 2021

Read More 'CRBP' Stories Here

CRBP Price Returns

1-mo -9.47%
3-mo -13.34%
6-mo -66.06%
1-year -83.87%
3-year -95.89%
5-year -95.35%
YTD -51.27%
2021 -50.74%
2020 -77.11%
2019 -6.51%
2018 -17.75%
2017 -15.98%

Continue Researching CRBP

Here are a few links from around the web to help you further your research on Corbus Pharmaceuticals Holdings Inc's stock as an investment opportunity:

Corbus Pharmaceuticals Holdings Inc (CRBP) Stock Price | Nasdaq
Corbus Pharmaceuticals Holdings Inc (CRBP) Stock Quote, History and News - Yahoo Finance
Corbus Pharmaceuticals Holdings Inc (CRBP) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8013 seconds.